Table 4 of Pelikan, Mol Vis 2013; 19:1453-1470.
Factors | Before the challenge | After the challenge (h) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
1/2 | 1 | 2 | 4 | 6 | 8 | 10 | 12 | 24 | 28 | ||
Histamine ng/ml | |||||||||||
- SLCR | <1.0 | <1.0 | 3.3±0.5* | 4.9±1.2* | 3.5±0.7* | <1.0 | <1.0 | <1.0 | 1.1±0.1 | <1.0 | <1.0 |
- PBS | <1.0 | <1.0 | <1.0 | <1.0 | <1.0 | <1.0 | <1.0 | <1.0 | <1.0 | <1.0 | <1.0 |
ECP µg/l | |||||||||||
- SLCR | 2.3±0.1 | 3.0±0.7 | 8.8±1.3* | 9.2±0.8* | 12.5±0.7* | 9.9±1.0* | 9.3±1.4* | 3.0±0.5 | <2.0 | <2.0 | <2.0 |
- PBS | 2.5±0.4 | 2.1±0.1 | <2.0 | <2.0 | <2.0 | <2.0 | <2.0 | <2.0 | <2.0 | <2.0 | <2.0 |
LTB4 pg/ml | |||||||||||
- SLCR | <4.8 | <4.8 | 5.8±1.3 | 9.4±0.7* | 16.6±1.8* | 14.9±1.1* | 8.5±1.2* | 6.1±0.7 | <4.8 | <4.8 | 5.2±0.3 |
- PBS | <4.8 | <4.8 | <4.8 | <4.8 | <4.8 | <4.8 | <4.8 | <4.8 | 5.1±0.2 | <4.8 | <4.8 |
LTC4 pg/ml | |||||||||||
- SLCR | 2.4±0.3 | <2.1 | <2.1 | 5.5±0.4* | 6.0±1.2* | 5.9±0.8* | 2.2±0.1 | 2.6±0.3 | <2.1 | <2.1 | <2.1 |
- PBS | 2.2±0.1 | <2.1 | <2.1 | <2.1 | <2.1 | 2.3±0.2 | <2.1 | <2.1 | <2.1 | <2.1 | <2.1 |
MPO ng/ml | |||||||||||
- SLCR | <25.0 | <25.0 | <25.0 | <25.0 | 39.4±3.0* | 48.1±2.6* | 45.9±4.2* | <25.0 | <25.0 | <25.0 | <25.0 |
- PBS | <25.0 | <25.0 | <25.0 | <25.0 | <25.0 | <25.0 | <25.0 | <25.0 | <25.0 | <25.0 | <25.0 |
IL-4 pg/ml | |||||||||||
- SLCR | 1.3±0.4 | <0.7 | <0.7 | <0.7 | 6.2±1.3* | 8.9±0.6* | 5.1±0.2* | <0.7 | <0.7 | <0.7 | <0.7 |
- PBS | 0.8±0.1 | <0.7 | <0.7 | <0.7 | <0.7 | <0.7 | 1.0±0.3 | <0.7 | <0.7 | <0.7 | <0.7 |
IL-5 pg/ml | |||||||||||
- SLCR | 3.5±0.3 | <3.2 | <3.2 | 7.1±0.8* | 6.5±0.6* | 4.9±0.3 | <3.2 | <3.2 | <3.2 | <3.2 | <3.2 |
- PBS | <3.2 | <3.2 | <3.2 | <3.2 | <3.2 | <3.2 | <3.2 | <3.2 | <3.2 | <3.2 | <3.2 |